Komori
Business Alliances4886ASKA Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Notice of Execution of an Agreement to Transfer the Marketing Authorization and Commercial Rights, Among Other Rights, for the Postmenopausal Osteoporosis Treatment Weelnara Combination Tablets

Asuka Pharmaceutical entered into an agreement with Bayer Yakuhin to acquire the marketing authorization and commercial rights, among other rights, in Japan for Weelnara Combination Tablets, a postmenopausal osteoporosis treatment manufactured and marketed by Bayer Yakuhin. Bayer Yakuhin's sales structure will remain in place until the transfer is completed, after which Asuka Pharmaceutical is scheduled to handle information provision and other activities.

Worth reading
35Immaterial
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Avoiding a definitive answer
How definitive the wording is.

Agreements reached under this partnership

4886ASKA Pharmaceutical Holdings Co.,Ltd.
Alliance partnerBayer Yakuhin, Ltd.
Details of the alliance
  1. 1

    Asuka Pharmaceutical is scheduled to assume the marketing authorization for the product.

  2. 2

    After completion of the transfer, work to maintain and secure a stable and continuous supply structure for the product

  3. 3

    After completion of the transfer, Asuka Pharmaceutical is scheduled to provide information on the product and conduct activities to promote its proper use.

These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.

About the partner
Business DescriptionManufactures and markets the product
LocationOsaka City
Impact on Business Performance

The impact of this matter on the Company's consolidated results for the current fiscal year is immaterial.

Contract Date4 November 2026
Agreements reached under this partnership
ItemDetails
Name of alliance partnerBayer Yakuhin, Ltd.
Alliance partner's business activitiesManufactures and markets the product
Alliance partner's locationOsaka City
Details of the allianceAsuka Pharmaceutical is scheduled to assume the marketing authorization for the product., After completion of the transfer, work to maintain and secure a stable and continuous supply structure for the product, After completion of the transfer, Asuka Pharmaceutical is scheduled to provide information on the product and conduct activities to promote its proper use.
Contract Date4 November 2026
Impact on Business PerformanceThe impact of this matter on the Company's consolidated results for the current fiscal year is immaterial.
Items this document does not state (17)
Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeType of allianceNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To maintain and secure a stable and continuous supply structure for the product after completion of the transfer, and to further promote initiatives addressing the diverse healthcare needs of women.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.